Reprogramming immune responses: Enabling cellular therapies and regenerative medicine

Stem Cells

Volumn 21, Issue 1, 2003, Pages 21-32

  Down, Julian D ^a   White Scharf, Mary E ^a,b  

^a BioTransplant Inc   (United States)

^b NONE   (United States)

Author keywords

Cellular therapy; Immune system; Immunosuppression; Reprogramming; Stem cells; Tolerance

Indexed keywords

BUSULFAN; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; MONOCLONAL ANTIBODY;

ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC RESTRICTION; BONE MARROW TRANSPLANTATION; CELL DIFFERENTIATION; CELL HETEROGENEITY; CELL LINE; CELL POPULATION; CHIMERA; DNA MODIFICATION; GENETIC DISORDER; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; PATIENT CARE; SHORT SURVEY; STEM CELL; T LYMPHOCYTE SUBPOPULATION;

EID: 0037237505     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.21-1-21     Document Type: Short Survey

References (111)

1. Ferrari G, Cusella-De Angelis G, Coletta M et al. Muscle regeneration by bone marrow-derived myogenic progenitors. Science 1998;279:1528-1530.
2. Jackson KA, Majka SM, Wang H et al. Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin Invest 2001;107:1395-1402.
3. Jackson KA, Mi T, Goodell MA. Hematopoietic potential of stem cells isolated from murine skeletal muscle. Proc Natl Acad Sci USA 1999;96:14482-14486.
4. Lagasse E, Connors H, Al-Dhalimy M et al. Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat Med 2000;6:1229-1234.
5. Krause DS, Theise ND, Collector MI et al. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell 2001;105:369-377.
6. Galli R, Borello U, Gritti A et al. Skeletal myogenic potential of human and mouse neural stem cells. Nat Neurosci 2000;3:986-991.
7. Clarke DL, Johansson CB, Wilbertz J et al. Generalized potential of adult neural stem cells. Science 2000;288:1660-1663.
8. Odorico JS, Kaufman DS, Thomson JA. Multilineage differentiation from human embryonic stem cell lines. STEM CELLS 2001;19:193-204.
9. Anderson DJ, Gage FH, Weissman IL. Can stem cells cross lineage boundaries? Nat Med 2001;7:393-395.
10. Ying QL, Nichols J, Evans EP et al. Changing potency by spontaneous fusion. Nature 2002;416:545-548.
11. Terada N, Hamazaki T, Oka M et al. Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion. Nature 2002;416:542-545.
12. Koller MR, Manchel I, Maher RJ et al. Clinical-scale human umbilical cord blood cell expansion in a novel automated perfusion culture system. Bone Marrow Transplant 1998;21:653-663.
13. Gilmore GL, DePasquale DK, Lister J et al. Ex vivo expansion of human umbilical cord blood and peripheral blood CD34(+) hematopoietic stem cells. Exp Hematol 2000;28:1297-1305.
14. Lazzari L, Lucchi S, Rebulla P et al. Long-term expansion and maintenance of cord blood haematopoietic stem cells using thrombopoietin, Flt3-ligand, interleukin (IL)-6 and IL-11 in a serum-free and stroma-free culture system. Br J Haematol 2001;112:397-404.
15. Denning-Kendall PA, Evely R, Singha S et al. In vitro expansion of cord blood does not prevent engraftment of severe combined immunodeficient repopulating cells. Br J Haematol 2002;116:218-228.
16. McNiece IK, Almeida-Porada G, Shpall EJ et al. Ex vivo expanded cord blood cells provide rapid engraftment in fetal sheep but lack long-term engrafting potential. Exp Hematol 2002;30:612-616.
17. Bodnar AG, Ouellette M, Frolkis M et al. Extension of lifespan by introduction of telomerase into normal human cells. Science 1998;279:349-352.
18. Jiang XR, Jimenez G, Chang E et al. Telomerase expression in human somatic cells does not induce changes associated with a transformed phenotype. Nat Genet 1999;21:111-114.
19. Morales CP, Holt SE, Ouellette M et al. Absence of cancer-associated changes in human fibroblasts immortalized with telomerase. Nat Genet 1999;21:115-118.
20. Rufer N, Migliaccio M, Antonchuk J et al. Transfer of the human telomerase reverse transcriptase (TERT) gene into T lymphocytes results in extension of replicative potential. Blood 2001;98:597-603.
21. Lebkowski JS, Gold J, Xu C et al. Human embryonic stem cells: culture, differentiation, and genetic modification for regenerative medicine applications. Cancer J 2001;7(suppl 2):S83-S93.
22. Auchincloss Jr H. In search of the elusive Holy Grail: the mechanisms and prospects for achieving clinical transplantation tolerance. Am J Transplant 2001;1:6-12.
23. Kamradt T, Mitchison NA. Tolerance and autoimmunity. N Engl J Med 2001;344:655-664.
24. Sykes M. Mixed chimerism and transplant tolerance. Immunity 2001;14:417-424.
25. Anderson CC, Matzinger P. Immunity or tolerance: opposite outcomes of microchimerism from skin grafts. Nat Med 2001;7:80-87.
26. Delves PJ, Roitt IM. The immune system. First of two parts. N Engl J Med 2000;343:37-49.
27. Kisielow P, von Boehmer H. Development and selection of T cells: facts and puzzles. Adv Immunol 1995;58:87-209.
28. Jameson SC, Bevan MJ. T-cell selection. Curr Opin Immunol 1998;10:214-219.
29. + regulatory T cells induced by an agonist self-peptide. Nat Immunol 2001;2:301-306.
30. Vendetti S, Chai JG, Dyson J et al. Anergic T cells inhibit the antigen -presenting function of dendritic cells. J Immunol 2000;165:1175-1181.
31. Shevach EM. Certified professionals: CD4(+)CD25(+) suppressor T cells. J Exp Med 2001;193:F41-F46.
32. Papiemik M, de Moraes ML, Pontoux C et al. Regulatory CD4 T cells: expression of IL-2R alpha chain, resistance to clonal deletion and IL-2 dependency. Int Immunol 1998;10:371-378.
33. Le Douarin N, Corbel C, Bandeira A et al. Evidence for a thymus-dependent form of tolerance that is not based on elimination or anergy of reactive T cells. Immunol Rev 1996;149:35-53.
34. Metzler B, Wraith DC. Inhibition of T-cell responsiveness by nasal peptide administration: influence of the thymus and differential recovery of T-cell-dependent functions. Immunology 1999;97:257-263.
35. Waldmann H, Cobbold S. How do monoclonal antibodies induce tolerance? A role for infectious tolerance? Annu Rev Immunol 1998;16:619-644.
36. Sakaguchi S, Sakaguchi N, Asano M et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151-1164.
37. Asano M, Toda M, Sakaguchi N et al. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med 1996;184:387-396.
38. Saoudi A, Seddon B, Heath V et al. The physiological role of regulatory T cells in the prevention of autoimmunity: the function of the thymus in the generation of the regulatory T cell subset. Immunol Rev 1996;149:195-216.
39. Saoudi A, Seddon B, Fowell D et al. The thymus contains a high frequency of cells that prevent autoimmune diabetes on transfer into prediabetic recipients. J Exp Med 1996;184:2393-2398.
40. Taylor PA, Noelle RJ, Blazar BR. CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J Exp Med 2001;193:1311-1318.
41. + T-cell subsets in determining transplantation rejection or tolerance. Immunol Rev 2001;182:164-179.
42. Deftos ML, He YW, Ojala EW et al. Correlating notch signaling with thymocyte maturation. Immunity 1998;9:777-786.
43. Hoyne GF, Dallman MJ, Lamb JR. T-cell regulation of peripheral tolerance and immunity: the potential role for Notch signalling. Immunology 2000;100:281-288.
44. Hoyne GF, Le Roux I, Corsin-Jimenez M et al. Serratel-induced notch signalling regulates the decision between immunity and tolerance made by peripheral CD4(+) T cells. Int Immunol 2000;12:177-185.
45. Waldmann H. Therapeutic approaches for transplantation. Curr Opin Immunol 2001;13:606-610.
46. Heath WR, Carbone FR. Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol 2001;19:47-64.
47. Pulendran B, Banchereau J, Maraskovsky E et al. Modulating the immune response with dendritic cells and their growth factors. Trends Immunol 2001;22:41-47.
48. Lechler R, Ng WF, Steinman RM. Dendritic cells in transplantation - friend or foe? Immunity 2001;14:357-368.
49. O'Connell PJ, Li W, Wang Z et al. Immature and mature CD8alpha+ dendritic cells prolong the survival of vascularized heart allografts. J Immunol 2002;168:143-154.
50. Slavin S, Strober S, Fuks Z et al. Induction of specific tissue transplantation tolerance using fractionated total lymphoid irradiation in adult mice: long-term survival of allogeneic bone marrow and skin grafts. J Exp Med 1977;146:34-48.
51. Ildstad ST, Sachs DH. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature 1984;307:168-170.
52. Sharabi Y, Sachs DH. Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen. J Exp Med 1989;169:493-502.
53. Cobbold SP, Martin G, Qin S et al. Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance. Nature 1986;323:164-166.
54. Wekerle T, Sykes M. Mixed chimerism as an approach for the induction of transplantation tolerance. Transplantation 1999;68:459-467.
55. Durham MM, Bingaman AW, Adams AB et al. Cutting edge: administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chimerism and donor-specific tolerance without cytoreductive conditioning. J Immunol 2000;165:1-4.
56. Boyse EA, Lance EM, Carswell EA et al. Rejection of skin allografts by radiation chimaeras: selective gene action in the specification of cell surface structure. Nature 1970;227:901-903.
57. Steinmuller D, Lofgreen JS. Differential survival of skin and heart allografts in radiation chimaeras provides further evidence for Sk histocompatibility antigen. Nature 1974;248:796-797.
58. Fuchimoto Y, Huang CA, Yamada K et al. Mixed chimerism and tolerance without whole body irradiation in a large animal model. J Clin Invest 2000;105:1779-1789.
59. Horowitz MM, Bortin MM. Current status of allogeneic bone marrow transplantation. Clin Transpl 1990:41-52.
60. Bortin MM, Horowitz MM, Gale RP et al. Changing trends in allogeneic bone marrow transplantation for leukemia in the 1980s. JAMA 1992;268:607-612.
61. Armitage JO. Bone marrow transplantation. N Engl J Med 1994;330:827-838.
62. Thomas ED. Karnofsky Memorial Lecture. Marrow transplantation for malignant diseases. J Clin Oncol 1983;1:517-531.
63. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998;91:756-763.
64. Khouri IF, Keating M, Korbling M et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitorcell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998;16:2817-2824.
65. Carella AM, Champlin R, Slavin S et al. Mini-allografts: ongoing trials in humans. Bone Marrow Transplant 2000;25:345-350.
66. Childs R, Clave E, Contentin N et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999;94:3234-3241.
67. Molina AJ, Sandmaier BM, Storb R. Nonmyeloablative hematopoietic stem cell allografting. Curr Opin Organ Transplant 2000;5:366-371.
68. Giralt S, Thall PF, Khouri I et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001;97:631-637.
69. Spitzer TR. Nonmyeloablative allogeneic stem cell transplant strategies and the role of mixed chimerism. The Oncologist 2000;5:215-223.
70. Gleit ZL, Cameron AM, Fuchimoto Y et al. Persistent chimerism despite antidonor MHC in vitro responses in miniature swine following allogeneic hematopoietic cell transplantation. Transplantation 2002;74:1260-1266.
71. Huang CA, Fuchimoto Y, Scheier-Dolberg R et al. Stable mixed chimerism and tolerance using a nonmyeloablative preparative regimen in a large-animal model. J Clin Invest 2000;105:173-181.
72. Kawai T, Cosimi AB, Colvin RB et al. Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation 1995;59:256-262.
73. Spitzer TR, Delmonico F, Tolkoff-Rubin N et al. Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation 1999;68:480-484.
74. Butcher JA, Hariharan S, Adams MB et al. Renal transplantation for end-stage renal disease following bone marrow transplantation: a report of six cases, with and without immunosuppression. Clin Transplant 1999;13:330-335.
75. Remuzzi G. Cellular basis of long-term organ transplant acceptance: pivotal role of intrathymic clonal deletion and thymic dependence of bone marrow microchimerism-associated tolerance. Am J Kidney Dis 1998;31:197-212.
76. Stewart FM, Crittenden RB, Lowry PA et al. Long-term engraftment of normal and post-5-fluorouracil murine marrow into normal nonmyeloablated mice. Blood 1993;81:2566-2571.
77. van Os R, Down JD. Murine models of bone-marrow transplant conditioning. In: Teicher BA, ed. Tumor Models in Cancer Research. Totowa, NJ: Humana Press Inc., 2001:381-405.
78. Down JD, Boudewijn A, Dillingh JH et al. Relationships between ablation of distinct haematopoietic cell subsets and the development of donor bone marrow engraftment following recipient pretreatment with different alkylating drugs. Br J Cancer 1994;70:611-616.
79. Down JD, Westerhof GR, Boudewijn A et al. Thiotepa improves allogeneic bone marrow engraftment without enhancing stem cell depletion in irradiated mice. Bone Marrow Transplant 1998;21:327-330.
80. Sykes M, Szot GL, Swenson K et al. Separate regulation of peripheral hematopoietic and thymic engraftment. Exp Hematol 1998;26:457-465.
81. Sykes M, Szot GL, Swenson KA et al. Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning. Nat Med 1997;3:783-787.
82. Bachar-Lustig E, Rachamim N, Li HW et al. Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nat Med 1995;1:1268-1273.
83. + cell transplants. Exp Hematol 2000;28:119-127.
84. Adams AB, Durham MM, Kean L et al. Costimulation blockade, busulfan, and bone marrow promote titratable macrochimerism, induce transplantation tolerance, and correct genetic hemoglobinopathies with minimal myelosuppression. J Immunol 2001;167:1103-1111.
85. Down JD, Ploemacher RE. Transient and permanent engraftment potential of murine hematopoietic stem cell subsets: differential effects of host conditioning with gamma radiation and cytotoxic drugs. Exp Hematol 1993;21:913-921.
86. Down JD, Johnson KW, Morgan P et al. Role of donor T cells on induction of MHC-mismatched donor-type chimerism following non-myeloablative transplant conditioning. Blood 2001;98:S315b.
87. Westerhof GR, Ploemacher RE, Boudewijn A et al. Comparison of different busulfan analogues for depletion of hematopoietic stem cells and promotion of donor-type chimerism in murine bone marrow transplant recipients. Cancer Res 2000;60:5470-5478.
88. Andersson BS, Kashyap A, Gian V et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant 2002;8:145-154.
89. Andersson BS, Madden T, Tran HT et al. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant 2000;6:548-554.
90. Alyea EP, Neuberg D, Canning C et al. Nonmyeloablative conditioning with low dose intravenous busulfan and fludarabine is safe and sufficient to obtain allogeneic stem cell engraftment in patients with hematologic malignancies. Blood 2001;98:S185a.
91. Bornhauser M, Thiede C, Schuler U et al. Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin. Bone Marrow Transplant 2000;26:119-125.
92. Aiuti A, Slavin S, Aker M et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002;296:2410-2413.
93. Eissner G, Multhoff G, Gerbitz A et al. Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide. Blood 2002;100:334-340.
94. Kawai Y, Plunkett W. DNA repair induced by 4-hydroxycyclophosphamide permits fludarabine nucleotide incorporation and is associated with synergistic induction of apoptosis in quiescent human lymphocytes. Blood 1999;94:S655a.
95. Yamauchi T, Nowak BJ, Keating MJ et al. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 2001;7:3580-3589.
96. Childs R, Chernoff A, Contentin N et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000;343:750-758.
97. Slavin S. Immunotherapy of cancer with alloreactive lymphocytes. N Engl J Med 2000;343:802-803.
98. Down JD, Johnson KW, Morgan PG et al. Varying levels of MHC-mismatched donor-type chimerism and induction of immunological tolerance following different non-myeloablative transplant conditioning regimens. Blood 2000;96:S172a-S173a.
99. Taylor PA, Lees CJ, Waldmann H et al. Requirements for the promotion of allogeneic engraftment by anti-CD154 (anti-CD40L) monoclonal antibody under nonmyeloablative conditions. Blood 2001;98:467-474.
100. Andre P, Prasad KS, Denis CV et al. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med 2002;8:247-252.
101. Storb R, Etzioni R, Anasetti C et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood 1994;84:941-949.
102. McGlave PB, Shu XO, Wen W et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program. Blood 2000;95:2219-2225.
103. Shizuru JA, Jerabek L, Edwards CT et al. Transplantation of purified hematopoietic stem cells: requirements for overcoming the barriers of allogeneic engraftment. Biol Blood Marrow Transplant 1996;2:3-14.
104. Shizuru JA, Weissman IL, Kernoff R et al. Purified hematopoietic stem cell grafts induce tolerance to alloantigens and can mediate positive and negative T cell selection. Proc Natl Acad Sci USA 2000;97:9555-9560.
105. Rosenzweig M, Connole M, Glickman R et al. Induction of cytotoxic T lymphocyte and antibody responses to enhanced green fluorescent protein following transplantation of transduced CD34(+) hematopoietic cells. Blood 2001;97:1951-1959.
106. Fields PA, Arruda VR, Armstrong E et al. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9. Mol Ther 2001;4:201-210.
107. Ge Y, Powell S, Van Roey M et al. Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX. Blood 2001;97:3733-3737.
108. Bagley J, Bracy JL, Tian C et al. Establishing immunological tolerance through the induction of molecular chimerism. Front Biosci 2002;7:d1331-d1337.
109. Andersson G, Denaro M, Johnson K et al. Engraftment of EGFP-expressing bone marrow in non-myeloablatively conditioned recipients results in immunological tolerance towards EGFP-transgenic skin grafts. Mol Ther 2002;5:S400.
110. Kyba M, Perlingeiro RC, Daley GQ. HoxB4 confers definitive lymphoid-myeloid engraftment potential on embryonic stem cell and yolk sac hematopoietic progenitors. Cell 2002;109:29-37.
111. Kaufman DS, Hanson ET, Lewis RL et al. Hematopoietic colony-forming cells derived from human embryonic stem cells. Proc Natl Acad Sci USA 2001;98:10716-10721.